Online now! Online now! Small-molecule inhibitors of the protein kinase DYRK as potential therapeutic candidates in cancer #chembiol
Venkataramani et al. identify two potent, ATP-competitive inhibitors of DYRK1A, FC-2 and FC-3, which suppress EGFR-driven glioblastoma (GBM) growth. Inhibitor-resistant mutants confirm DYRK1A as the functional target, highlighting FC-2 and FC-3 as promising therapeutic candidates in EGFR-dependent GBM and other cancers.
